Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GALR2 | O43603 | 1/20 | 0.42 |
| ▸ | GALR1 | P47211 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423033 | 0.87 | PTPN11 (0.54) | PTPN11MAPTMEN1TSHRKMT2A | |
| SCHEMBL16339854 | 0.85 | HDAC3 (0.39) | MAPTMEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL16339293 | 0.83 | MAPT (0.54) | MAPTMEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL30312613 | 0.83 | PTPN11 (0.44) | PTPN11MAPTMEN1TSHRKMT2A | |
| SCHEMBL25096320 | 0.82 | PTPN11 (0.46) | PTPN11MAPTMEN1TSHRKMT2A | |
| SCHEMBL30217787 | 0.82 | PTPN11 (0.46) | PTPN11MAPTMEN1TSHRKMT2A | |
| SCHEMBL30217703 | 0.82 | BACE1 (0.40) | PTPN11MAPTGALR2GALR1MEN1 | |
| SCHEMBL25095784 | 0.82 | BACE1 (0.40) | PTPN11MAPTGALR2GALR1MEN1 | |
| SCHEMBL31211252 | 0.82 | PTPN11 (0.39) | PTPN11MAPTGALR2GALR1MEN1 | |
| SCHEMBL25095913 | 0.82 | MAPT (0.44) | PTPN11MAPTGALR2GALR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | Hoffmann-La Roche Inc. and PTC Therapeutics Inc. | 2018-08-09 | — | — | US | disclosed |
| EP-3013345-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN LA ROCHE (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3013345-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. Hoffmann-La Roche AG (CH) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209841-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222925-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | SUV39H2 2844/4885PTPN11 3935/4885MAPT 563/4885 |
| US-20160145270-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, PYGM | SUV39H2 2844/4885PTPN11 3935/4885MAPT 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.